Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) is a global leader in innovative eye care solutions, specializing in visioncare products and ophthalmic surgical equipment. This page aggregates official company announcements, financial disclosures, and strategic developments for stakeholders tracking its market position.
Access real-time updates on product innovations, regulatory milestones, and financial performance. Investors and industry professionals will find curated press releases covering earnings reports, partnership announcements, and clinical trial outcomes.
Key content includes updates on contact lens technologies, intraocular lens advancements, and surgical system innovations. All materials are sourced directly from Alcon's communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to Alcon's latest developments. Combine this resource with SEC filings and market analysis tools for comprehensive investment research.
Alcon (SIX/NYSE: ALC) has announced the launch of TOTAL30 for Astigmatism and DAILIES TOTAL1 for Astigmatism in Canada, expanding its range of innovative contact lenses for astigmatic patients. As the toric lens segment is rapidly growing, with only 10% of the 47% of patients needing correction currently using toric lenses, this launch addresses a significant market gap. The lenses utilize Alcon's proprietary Water Gradient technology, providing enhanced comfort and moisture retention. With added features like PRECISION BALANCE 8|4 lens design and CELLIGENT™ Technology, these products aim to improve wearers' experiences significantly.
Alcon (NYSE: ALC) has announced the launch of TOTAL30® for Astigmatism, the first reusable contact lens utilizing Water Gradient technology for astigmatic wearers. This innovative product enhances comfort and visual stability, targeting the $1.2 billion reusable toric lens market. Available in the U.S. and Europe from early 2023, TOTAL30 aims to improve the lens-wearing experience for astigmatic patients. The product features biomimetic CELLIGENT™ Technology to resist bacteria, ensuring a cleaner lens throughout the month.
Alcon (NYSE: ALC) CEO David Endicott will present at the 2023 J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 a.m. PST. A live webcast of the presentation will be available at investor.alcon.com/news-and-events/events-and-presentations. As a global leader in eye care, Alcon serves over 260 million people with products for conditions such as cataracts and glaucoma, emphasizing its commitment to enhancing sight and quality of life.
Alcon Inc. ('ALC') has launched a private offering of US$700 million in 5.375% senior notes due 2032 and US$600 million in 5.750% senior notes due 2052. The offering is set to close on December 6, 2022. Proceeds will be directed towards general corporate purposes, including repaying outstanding debts related to its acquisition of Aerie Pharmaceuticals, Inc. The notes will be issued by Alcon Finance Corporation and guaranteed by Alcon.
Alcon has successfully completed its acquisition of Aerie Pharmaceuticals for approximately $930 million. This acquisition strengthens Alcon's position in the $20 billion global ophthalmic pharmaceutical market, enhancing its product offerings with Rocklatan and Rhopressa, and adding AR-15512, a Phase 3 dry eye candidate. The deal will leverage Alcon’s commercial capabilities and expand its research and development expertise, supporting future growth. Alcon aims to fully integrate Aerie into its operations, building on previous acquisitions to enhance its ophthalmic pharmaceutical portfolio.
Alcon reported third quarter 2022 sales of $2.1 billion, reflecting a 2% increase year-over-year and a 9% rise in constant currency. Diluted earnings per share were $0.23, while core earnings per share were $0.50, down 7% on a reported basis but up 14% in constant currency. The updated 2022 outlook expects net sales between $8.5 billion and $8.7 billion, with a core operating margin tightening to 18.0%-18.5%. Challenges include foreign currency impacts and supply chain issues. The acquisition of Aerie Pharmaceuticals is anticipated to close in Q4 2022.
Alcon (NYSE: ALC) has announced the launch of the Clareon Toric intraocular lens, designed for U.S. cataract patients with astigmatism, featuring advanced stability technology. This product completes the Clareon Collection, which includes various IOL options. Additionally, Alcon will showcase its Fidelis Virtual Reality Surgical Simulator and patient engagement tools at the upcoming AAO 2022 conference in Chicago. Studies presented will highlight the effectiveness and patient satisfaction associated with Alcon's products, supporting their commitment to innovative eye care solutions.
Alcon has announced a definitive merger agreement to acquire Aerie Pharmaceuticals for approximately $770 million. The transaction is expected to enhance Alcon's capabilities in the $20 billion global ophthalmic pharmaceutical segment by adding products like Rocklatan® and Rhopressa®. The acquisition is anticipated to be accretive to Alcon's core diluted EPS in 2024. Aerie's glaucoma franchise net product revenue is projected at $130-140 million for 2022, with the transaction expected to close in Q4 2022, pending shareholder and regulatory approvals.
Alcon reported strong second quarter 2022 sales of $2.2 billion, a 5% increase from the previous year, and a significant 10% rise in constant currency. Though diluted earnings per share fell 3% to $0.30, core diluted EPS rose 13% to $0.63. The company's outlook for the full year was updated to net sales between $8.6 to $8.8 billion, reflecting consistent core operating margins but reduced expectations for core diluted EPS growth. Despite challenges from currency fluctuations, Alcon remains focused on new products and profitability improvements.
FAQ
What is the current stock price of Alcon (ALC)?
What is the market cap of Alcon (ALC)?
